Free tool
FAERS Monitor: Nuvessa
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 205223 or its brand name (Nuvessa, Metronidazole). Reports on generic versions are filed under their own applications.
Reports
48,241
Serious
42,012
87% of reports
Hospitalization
19,881
Death reported
5,419
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective4,672
- nausea3,469
- off label use3,384
- diarrhoea2,721
- vomiting2,342
- pyrexia2,301
- headache2,261
- abdominal pain2,126
- pain2,121
- fatigue1,960
- dizziness1,689
- condition aggravated1,638
- dyspnoea1,595
- acute kidney injury1,545
- malaise1,468
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 459 |
| 2005 | 480 |
| 2006 | 482 |
| 2007 | 511 |
| 2008 | 320 |
| 2009 | 676 |
| 2010 | 858 |
| 2011 | 1,164 |
| 2012 | 1,431 |
| 2013 | 1,112 |
| 2014 | 1,451 |
| 2015 | 2,167 |
| 2016 | 2,469 |
| 2017 | 2,511 |
| 2018 | 4,196 |
| 2019 | 4,496 |
| 2020 | 3,830 |
| 2021 | 3,904 |
| 2022 | 3,418 |
| 2023 | 3,478 |
| 2024 | 3,179 |
| 2025 | 3,456 |
| 2026 | 2,190 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,005,918 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| acute kidney injurySignal | 1,545 | 4.4 | 4.2 | 4,097 |
| abdominal painSignal | 2,126 | 4.0 | 3.8 | 4,814 |
| pyrexiaSignal | 2,301 | 2.9 | 2.8 | 2,916 |
| condition aggravatedSignal | 1,638 | 2.4 | 2.2 | 1,289 |
| vomitingSignal | 2,342 | 2.2 | 2.1 | 1,517 |
| nausea | 3,469 | 1.9 | 1.9 | 1,568 |
| diarrhoea | 2,721 | 1.8 | 1.8 | 1,074 |
| off label use | 3,384 | 1.7 | 1.6 | 985 |
| headache | 2,261 | 1.6 | 1.5 | 486 |
| drug ineffective | 4,672 | 1.5 | 1.5 | 962 |
| pain | 2,121 | 1.5 | 1.4 | 371 |
| dizziness | 1,689 | 1.5 | 1.4 | 266 |
| malaise | 1,468 | 1.5 | 1.4 | 217 |
| dyspnoea | 1,595 | 1.2 | 1.2 | 70 |
| fatigue | 1,960 | 1.1 | 1.1 | 18 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.